Mineralys Therapeutics, Inc. MLYS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| -$154.65M+13.0% | -$177.81M-147% | -$71.9M-141% | ||
| $59K+37.2% | $43K— | $0— | ||
| $19.32M+70.5% | $11.34M+124% | $5.06M+1,012% | ||
| -$142.42M+14.4% | -$166.31M-105% | -$81.17M-178% | ||
| -$389.75M-439% | $114.96M+170% | -$164.48M— | ||
| $591M— | —— | $203.83M— | ||
| —— | —— | -$38.4M— | ||
| -$142.43M+14.4% | -$166.41M-105% | -$81.17M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Mineralys Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.